

## **Rami S. Komrokji, MD**

Dr. Komrokji is the Vice chair of the Malignant Hematology Department at the Moffitt Cancer Center, Tampa, Florida.

He is a senior Member of the Malignant Hematology and Experimental Therapeutics Program at the Moffitt Cancer Center, and Professor in Medicine & Oncologic Sciences at the College of Medicine, at the University of South Florida in Tampa, Florida.

After earning a medical degree in 1996 from the Jordan University School of Medicine, Dr. Komrokji completed an internship and residency at Case Western University, St. Vincent Program. He then completed a fellowship at Strong Memorial Hospital, University of Rochester, in Hematology/Oncology and Hematopoietic Stem Cell Transplantation.

Dr Komrokji is expert in myeloid neoplasms where he led several clinical trials and lectured worldwide. His work paved the FDA approval for luspatercept in myelodysplastic syndromes and for Pacritinib in myelofibrosis.

He has authored or co-authored more than 380 peer-reviewed manuscripts, 20 book chapters, and more than 1000 abstracts in Hematologic Malignancies. He served as member on the MDS Panel of the National Comprehensive Cancer Network (NCCN) and currently member of the NHLBI MDS natural history study steering committee and aplastic anemia and MDS foundation medical board of directors. He was member of the editorial board for Journal of Clinical Oncology (JCO). He is peer reviewer for several medical journals including Blood Journal, JCO and Leukemia Journal. He is a regularly invited speaker at national and international meetings and had won several awards in recognition of his work.

Dr. Komrokji's research interests are in Phase I and II Clinical Trials, and in the outcome research in hematologic malignancies with focus on myeloid neoplasms. His clinical interests are Myelodysplastic syndromes (MDS), Acute Myeloid Leukemias, and Myeloproliferative neoplasms.